Curcumin improves sclerosing cholangitis in $Mdr2^{-/-}$ mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation

Anna Baghdasaryan,¹ Thierry Claudel,¹ Astrid Kusters,² Judith Gumhold,¹ Dagmar Silbert,¹ Andrea Thüringer,³ Katharina Leski,¹ Peter Fickert,¹ Saul J Karpen,^{2,4} Michael Trauner¹

A commentary on this article will appear in the May issue

► See companion paper GUT/2009/201954.

¹Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria
²Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Texas Children's Liver Center, Houston, Texas, USA

³Institute of Pathology, Medical University Graz, Graz, Austria

⁴Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA

Correspondence to

Professor Michael Trauner, Laboratory of Experimental and Molecular Hepatology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University Graz, Auenbruggerplatz 15, A-8036 Graz, Austria; michael.trauner@meduni-graz.at

Revised 13 October 2009
Accepted 29 October 2009

ABSTRACT

Background and aim Chronic cholangiopathies have limited therapeutic options and represent an important indication for liver transplantation. Curcumin, the yellow pigment of the spice turmeric, has pleiotropic actions and attenuates hepatic damage in animal models of chemically-induced liver injury. Whether curcumin has beneficial effects in cholangiopathies is unknown.

Methods Potential anticholestatic, anti-inflammatory and antifibrotic mechanisms of curcumin were explored in vivo in $Mdr2^{-/-}$ mice as a murine model of chronic cholangiopathy; as well as in vitro in a cholangiocyte cell line (HuCCT1) and portal myofibroblasts (MFBs) isolated from $Mdr2^{-/-}$ mice.

Results Liver damage, cholestasis and fibrosis were reduced in $Mdr2^{-/-}$ mice after curcumin feeding. Moreover, curcumin inhibited cholangiocyte proliferation and expression of activation marker vascular cell adhesion molecule-1 in $Mdr2^{-/-}$ mice. Curcumin—similar to PPAR γ synthetic agonist troglitazone—directly inhibited TNF- α -induced inflammatory activation of cholangiocytes in vitro, whereas these beneficial effects of curcumin were largely blocked by a PPAR γ synthetic antagonist. In addition, curcumin blocked proliferation and activation of portal MFBs by inhibiting ERK1/2 phosphorylation, thus contributing to reduced fibrogenesis.

Conclusions These results show that curcumin may have multiple targets in liver including activation of PPAR γ in cholangiocytes and inhibition of ERK1/2 signalling in MFBs, thereby modulating several central cellular events in a mouse model of cholangiopathy. Targeting these pathways may be a promising therapeutic approach to cholangiopathies.

Chronic cholangiopathies such as primary sclerosing cholangitis (PSC) and primary biliary cirrhosis are characterised by progressive inflammation and subsequent development of biliary fibrosis and cirrhosis.^{1,2} Since the effectiveness of currently available medical therapies to slow the progression of cholangiopathies is limited, there is an urgent need for novel and effective medical treatment strategies. Importantly, cholangiocytes may undergo phenotypic and functional modifications, characterised by production of pro-inflammatory and profibrogenic mediators, thus contributing to propagation and progression of liver diseases.^{3–5} Therefore, it is attractive to hypothesise that

targeting the bile duct inflammatory phenotype may be beneficial in treatment of cholangiopathies.

Curcumin, a non-steroidal yellow pigment found in rhizomes of the perennial herb *Curcuma longa*, has been used for centuries in Ayurvedic medicine to cure a wide range of gastrointestinal disorders, and is a component of the spice turmeric.^{6–11} In rodent models of chemically induced liver damage and fibrosis such as carbon tetrachloride and thioacetamide-induced liver cirrhosis, curcumin was shown to have anti-inflammatory, antioxidative and antifibrotic properties.^{12–15} Moreover, blocking c-Jun N-terminal kinase (JNK) signalling by curcumin was shown to inhibit inflammation-mediated alterations of hepatobiliary transporter gene expression in hepatocytes.¹⁶ However, to date no study has addressed the effects of curcumin on bile duct inflammation and liver damage in cholangiopathies. We therefore designed a longitudinal study to explore potential molecular mechanisms of curcumin in multidrug-resistant protein 2 knockout ($Mdr2^{-/-}$) mice serving as a genetic model of progressive cholangiopathy with biliary fibrosis.^{17–21}

We herein demonstrate that curcumin reduces liver damage, cholangitis and biliary fibrosis in $Mdr2^{-/-}$ mice most likely by acting on multiple targets: inhibiting the inflammatory phenotype of bile duct epithelial cells through PPAR γ activation and blocking proliferation/activation of portal myofibroblasts (MFBs) through inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) signalling.

MATERIALS AND METHODS

Animal experiments

$Mdr2^{-/-}$ mice (FVB/N background) were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and housed with a 12:12 hour light/dark cycle with water and a mouse diet (Harlan Teklad, Madison, WI, USA) ad libitum. Male mice were used exclusively. Experimental protocols were approved by the local Animal Care and Use Committee according to criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by US National Academy of Sciences (National Institutes of Health publication 86–23, revised 1985).

Feeding protocols

Feeding of control and curcumin-enriched (4% wt/wt) diets in $Mdr2^{-/-}$ mice was performed for 4 and 8 weeks starting at the age of 4 weeks, a time point

when the principal features of bile duct disease and biliary fibrosis are already present and show high activity.^{17–22} Curcumin was kindly gifted by Sabinsa Corporation in form of Curcumin C3 complex (Sabinsa Utah, Payson, UT, USA), which contained 96.24% curcuminoids, of which 72.1% was curcumin, 21.98% demethoxy curcumin and 5.91% bisdemethoxy curcumin. Wild type (WT) mice of the same age received a control diet (Harlan Teklad, Madison, WI, USA).

Food intake, body weight/liver weight measurement

Food intake was controlled at days 1, 3 and 7 during the first week, and further monitored once a week, whereas gain in body weight (BW) was monitored daily. Liver weight (LW) was compared to the BW and the percentage ratio was calculated (LW/BW).

Routine serum biochemistry

Blood was collected at harvesting and centrifuged for 15 min at 4500 rpm. Serum was stored at -80°C until analysis. Assays for alanine aminotransferase and alkaline phosphatase were routinely measured, whereas serum bile acid (BA) concentration was determined by using Bile Acid Kit (Ecoline S+ from DiaSys Diagnostic Systems GmbH, Holzheim, Germany) in a Hitachi 917 analyser (Boehringer Mannheim, Mannheim, Germany).

Liver histology

For conventional light microscopy, livers were fixed in 4% neutral buffered formaldehyde solution for 24 h and embedded in paraffin. Sections were cut 2 μm thick and stained with haematoxylin and eosin (H&E) or Sirius red.

Determination of hepatic hydroxyproline content

To quantify liver fibrosis, hepatic hydroxyproline (HP) was measured from standardised liver lobe as described previously.²³

Immunohistochemistry

Detection of proliferation marker Ki-67, cholangiocyte cytoskeleton marker keratin 19 (K19), vascular cell adhesion molecule-1 (VCAM-1), neutrophil granulocyte marker CD-11b and lymphocyte markers CD4 and CD8 was performed as described.^{17–18}

Western blotting for hepatic K19 and hepatocellular transporters Ntcp, Bsep, Mrp2 and Mrp3

Total proteins from liver homogenates were isolated as described²⁴ and protein concentrations were determined using a Bradford kit (BioRad, Richmond, CA, USA). Western blotting for K19 was performed as previously described.¹⁸ For hepatocellular transporters, preparation of liver membranes, detection of immunocomplexes as well as densitometric quantification of band intensities, was performed as described.^{25–26}

Measurement of bile flow and composition

Bile flow and output of biliary phospholipids (PLs), BAs, cholesterol and glutathione were determined as previously described.¹⁸ Experimental feeding was initiated in 4-week-old $\text{Mdr2}^{-/-}$ and WT mice. After 7 days of feeding either a control or a curcumin-enriched diet, mice were anaesthetised (10 mg of avertin intraperitoneally), abdominal cavity was opened, common bile duct was ligated and gallbladder was cannulated. After a 10 min equilibration period, bile was collected in pre-weighed tubes for 30 min. Bile flow was determined gravimetrically and normalised to LW. Samples were kept frozen at -20°C until analysis.

Messenger RNA analysis and Polymerase Chain Reaction (PCR)

RNA isolation, complementary DNA synthesis, and real-time PCR were performed as described previously.²⁷

Isolation, culture and experiments with portal myofibroblasts

Portal MFBs were isolated as described.²⁸ Briefly, the biliary tree was isolated from 12-week-old $\text{Mdr2}^{-/-}$ mice by collagenase and pronase digestion. Portal tract residues were allowed to adhere in Petri dishes and cultured in DMEM medium (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% foetal calf serum (FCS) and 1% penicillin/streptomycin. After 2–3 days an extensive outgrowth and adherence of portal MFBs was observed around biliary structures. Purification of portal MFBs from other cells was obtained through serial passages and cell type analysis was made by immunofluorescence staining for hepatocellular

Figure 1 Curcumin reduces liver damage and cholestasis in $\text{Mdr2}^{-/-}$ mice. A. Chow- as well as curcumin-fed wild type mice (WT and WT+Cu) demonstrate normal liver structure (H&E). Representative liver histology of 8-week-old $\text{Mdr2}^{-/-}$ mouse shows sclerosing cholangitis. Curcumin feeding for 4 weeks reduces bile duct damage as well as periductal fibrosis in $\text{Mdr2}^{-/-}$ mouse ($\text{Mdr2}^{-/-}$ + Cu) compared with age-matched littermate. B. Curcumin feeding in WT mice is non-toxic as shown by unchanged serum parameters of liver injury (ALT) and cholestasis (AP and BAs). Compared with WT mice, untreated $\text{Mdr2}^{-/-}$ mice show increased serum parameters of liver injury (ALT) and cholestasis (AP and BAs), whereas $\text{Mdr2}^{-/-}$ + Cu mice have significantly reduced serum biochemical parameters of liver damage and cholestasis. Values are means $\pm$ SD from five animals per group. * $p < 0.05$ $\text{Mdr2}^{-/-}$ vs WT, # $p < 0.05$ $\text{Mdr2}^{-/-}$ + Cu vs $\text{Mdr2}^{-/-}$. ALT, alanine aminotransferase; AP, alkaline phosphatase; BAs, bile acids; bd, bile duct; pv, portal vein.

cytoskeleton marker K8/18, activated MFB marker α -SMA and nuclear marker DAPI. The majority of isolated cell population was α -SMA-positive and K8/18-negative, demonstrating sufficient purity (data not shown). Cells from passage 8–20 were used for experiments. Cell viability was tested by trypan blue dye exclusion after 24 h of curcumin incubation. At concentrations of 10 and 20 μ M curcumin did not induce MFB death, while 30 μ M was toxic; therefore, 10 and 20 μ M concentrations were subsequently used for in vitro experiments. In proliferation studies, portal MFBs were stained for proliferation marker Ki-67. Nuclear and cytoplasmic proteins were isolated by using a Pierce kit (NE-PER Nuclear and Cytoplasmic Extraction Reagents, Rockford, IL, USA). Western blotting for NF- κ B and pERK was performed by using polyclonal rabbit antibodies against NF- κ B (dilution 1:2000) (NeoMarkers, Fremont, CA, USA) and pERK1/2 (dilution 1:1000) (Cell Signalling Technology, Inc, Danvers, MA, USA). Specific binding was detected by secondary anti-rabbit antibody (dilution 1:3000) (Cell Signalling Technology, Inc, Danvers, MA, USA). Equal protein loading was confirmed by Coomassie blue staining of gels and Ponceau S staining of membranes.

Cholangiocyte culture experiments

Cholangiocarcinoma cell line (HuCCT1) was obtained from Japan Health Sciences Foundation Resources Bank, Osaka, Japan. Cells were incubated in RPMI culture medium (PAA Laboratories GmbH, Pasching, Austria) with 10% FCS and used for experiments at 80% confluence. TNF- α and troglitazone were from Sigma-Aldrich Chemie, GmbH, Steinheim, Germany. Bisphenol A diglycidyl ether (BADGE) was obtained from Sigma-Aldrich, Vienna, Austria. Cytotoxicity of curcumin was tested by trypan blue dye exclusion method.

Statistical analysis

Results were evaluated using SPSS V.14.0. Statistical analysis was performed using one-way analysis of variance test followed by Mann-Whitney. Data are reported as means of five animals per group (unless otherwise noted) $\pm$ SD. A *p* value ≤ 0.05 was considered significant.

Figure 2 Hepatic fibrosis is reduced in $Mdr2^{-/-}$ mice by curcumin. **A**, Sirius red staining did not differ between chow-fed and curcumin-fed wild type mice (WT and WT+Cu respectively). Representative Sirius red staining shows pronounced fibrosis with collagen deposition (red) around bile ducts in $Mdr2^{-/-}$ mouse (arrowheads) compared with WT mouse. Four-week curcumin-treated $Mdr2^{-/-}$ mouse ($Mdr2^{-/-}$ +Cu) demonstrates reduced collagen deposition compared with age matched untreated littermate (original magnification $\times 20$). **B**, Hepatic hydroxyproline (HP) content is significantly reduced by curcumin in $Mdr2^{-/-}$ mice. **C**, Curcumin feeding significantly inhibits hepatic Col1 $\alpha 2$ mRNA level in $Mdr2^{-/-}$ mice. Expression levels are normalised to 18s gene expression and levels of WT are expressed as 1. Values are presented as means $\pm$ SD from 4–5 mice per group. *p < 0.05 $Mdr2^{-/-}$ vs WT, #*p* < 0.05 $Mdr2^{-/-}$ + Cu vs $Mdr2^{-/-}$, bd, bile duct; pv, portal vein.

RESULTS

Curcumin significantly reduces liver damage and cholestasis in $Mdr2^{-/-}$ mice

We first addressed whether curcumin-enriched diet was well tolerated by $Mdr2^{+/+}$ (WT) and $Mdr2^{-/-}$ mice. Survival rate (100%) and food consumption (average: 4–5 g/day) did not differ between study groups. LW/BW ratio was increased in 8-week-old $Mdr2^{-/-}$ mice compared with age-matched WT mice and remained unchanged after curcumin feeding (data not shown). Curcumin feeding reduced sclerosing cholangitis, ductular proliferation (figure 1A), serum liver enzymes (alanine aminotransferase and alkaline phosphatase) and BA levels in $Mdr2^{-/-}$ mice (figure 1B) after 4 weeks of feeding. Compared with 4-week-feeding, prolonged curcumin feeding for 8 weeks did not result in a further reduction of serum liver enzymes (figure 3B,C). Taken together, these data demonstrated beneficial effects of curcumin on cholestatic phenotype in $Mdr2^{-/-}$ mice.

Hepatic fibrosis in $Mdr2^{-/-}$ mice is significantly reduced by curcumin

Biliary fibrosis, determined by Sirius red staining, measurement of hepatic HP levels and Col1 $\alpha 2$ mRNA expression, was reduced in $Mdr2^{-/-}$ mice after 4 weeks of curcumin feeding (figure 2A–C). With age untreated $Mdr2^{-/-}$ mice showed progression of fibrosis as determined by increased hepatic HP levels (243 ± 45.8 at 12 weeks vs $166 \pm 3.1 \mu$ g/g LW at 8 weeks). Prolonged curcumin feeding (figure 3D) resulted in a more pronounced relative reduction of HP levels (42.7% after 8-week-feeding vs 21.9% reduction after 4-week-feeding), but did not further decrease HP levels compared with 4-week-feeding (139 ± 12 vs $129.6 \pm 15 \mu$ g/g LW, not significant). Taken together, these findings suggest that curcumin feeding had no effect on resolution, but rather reduced progression of hepatic fibrosis in $Mdr2^{-/-}$ mice via inhibition of collagen production.

Curcumin increases bile flow and biliary glutathione output in $Mdr2^{-/-}$ mice

Since liver disease in $Mdr2^{-/-}$ mice primarily results from toxic bile composition due to increased concentrations of non-micellar

Figure 3 Curcumin feeding for 8 weeks reduces liver damage and fibrosis in *Mdr2*^{-/-} mice. A. Schematic illustration of feeding protocols in *Mdr2*^{-/-} mice. Experimental feeding in *Mdr2*^{-/-} mice was initiated at the age of 4 weeks, when the ductular proliferation and fibrosis showed high activity and lasted for 4 or 8 weeks. Feeding of age matched wild type mice followed the same experimental protocol. B. Serum liver enzymes and hepatic hydroxyproline were measured in *Mdr2*^{-/-} mice to quantify liver damage and fibrosis after 8 weeks of curcumin feeding. Curcumin reduces serum liver enzymes ALT and AP as well as fibrosis in *Mdr2*^{-/-} mice after 8 weeks of feeding. Values are presented as means $\pm$ SD from four animals per group. #*p* < 0.05 *Mdr2*^{-/-} + Cu vs *Mdr2*^{-/-}. ALT, alanine aminotransferase; AP, alkaline phosphatase; HP, hydroxyproline.

bound BAs,²⁹ we next addressed whether curcumin modified bile formation and output of main biliary constituents. To distinguish between direct effects on bile flow and liver healing properties of curcumin, 4-week-old WT and *Mdr2*^{-/-} mice were fed short-term (7 days) either a control or a curcumin-enriched diet. In WT mice, curcumin increased bile flow and biliary glutathione output, but did not modify biliary BA, PL and cholesterol output (table 1). Compared with WT mice, biliary PL and cholesterol output was dramatically reduced in *Mdr2*^{-/-} mice and remained unchanged after curcumin feeding. In addition, curcumin increased bile flow in *Mdr2*^{-/-} mice and restored altered biliary glutathione output (table 1). However, total hepatic glutathione content did not differ between the groups (data not shown), suggesting that curcumin had no impact on hepatic glutathione synthesis. Collectively, these data show that curcumin increased bile flow and biliary glutathione output, but did not modify bile toxicity as reflected by unchanged biliary PL, cholesterol and BA output.

Therapeutic effects of curcumin in *Mdr2*^{-/-} mice are neither mediated by changes of bile acid transport nor synthesis

Reduction of serum BA levels in curcumin-treated *Mdr2*^{-/-} mice may reflect alterations of BA transport and synthesis. Neither expression of the main sinusoidal BA importer (Ntcp) nor canalicular BA/anion exporters (Bsep, Mrp2, Mrp3) were altered by curcumin feeding in *Mdr2*^{-/-} mice (figure 4A). Expression of Cholesterol 7 α -hydroxylase (Cyp7 α 1), the rate limiting enzyme for BA synthesis also did not differ significantly between WT, *Mdr2*^{-/-} and curcumin-treated *Mdr2*^{-/-} mice (figure 4B). Taken together, these data indicate that curcumin had no effect on hepatic BA homeostasis in *Mdr2*^{-/-} mice.

Curcumin reduces proliferation of activated portal myofibroblasts and inhibits ERK signalling

Since activated portal MFBs represent an important source for the extracellular matrix in *Mdr2*^{-/-} mice, we next studied direct antifibrotic mechanisms of curcumin in portal MFBs. Since isolated MFBs as well as hepatic stellate cells (HSCs) demonstrate high proliferation rate and activity upon contact with the plastic, we used 0% FCS to inhibit MFB activation and synchronise the cells and 10% FCS to stimulate MFB activation. Compared with 0% FCS condition, 10% FCS stimulated prolif-

eration as well as expression of fibrogenic markers in portal MFBs (figure 5B,C), while curcumin at 10 and 20 μ m, two doses shown to be nontoxic (figure 5A), reduced 10% FCS-induced proliferation of portal MFBs (figure 5B). We next studied PPAR γ

Figure 4 Transport of biliary constituents and bile acid synthesis are not affected by curcumin in *Mdr2*^{-/-} mice. A. Liver membranes for Western blotting were isolated from wild type (WT) and *Mdr2*^{-/-} mice fed either a control or a curcumin-enriched diet for 4 weeks. Curcumin feeding does not influence levels of key hepatocellular transporters in *Mdr2*^{-/-} mice (*Mdr2*^{-/-} + Cu). Densitometry data are expressed as fold change relative to WT group. Values are means from three to four animals per group. β -actin protein levels were used as a protein loading control. *p < 0.05 *Mdr2*^{-/-} and *Mdr2*^{-/-} + Cu vs WT. B. Cyp7 α 1 gene expression does not differ between WT, WT + Cu, *Mdr2*^{-/-} and *Mdr2*^{-/-} + Cu groups. Expression levels are normalised to 18s gene expression and levels of WT are expressed as 1. Values are presented as means $\pm$ SD from five animals per group. Ntcp, Na⁺/taurocholate cotransporting polypeptide; Mrp2, multidrug resistance associated protein 2; Mrp3, multidrug resistance associated protein 3; Bsep, bile salt export pump; Cyp7 α 1, cholesterol 7 α -hydroxylase.

Table 1 Curcumin effects on bile flow and composition in wild type and *Mdr2*^{-/-} mice

Variable	WT	WT+Cu	<i>Mdr2</i> ^{-/-}	<i>Mdr2</i> ^{-/-} +Cu
Bile flow (μl/g LW/min)	1.3±0.2	1.7±0.2‡	1.2±0.2	1.8±0.2‡
Bile acids (nmol/g LW/min)	28.1±6.5	38.2±10.1	27.4±1.7	30.1±14.4
Cholesterol (nmol/g LW/min)	0.6±0.2	0.6±0.1	0.1±0.0*	0.2±0.0*
Glutathione (nmol/g LW/min)	4.0±0.7	8.4±1.4‡	1.2±0.3*	4.9±1.1‡
Phospholipids (nmol/g LW/min)	4.5±0.7	4.7±1.1	0.3±0.1*	0.5±0.1*

*p<0.05 *Mdr2*^{-/-} and *Mdr2*^{-/-}+Cu vs WT.‡*p*<0.05 *Mdr2*^{-/-}+Cu vs *Mdr2*^{-/-}.‡*p*<0.05 WT+Cu vs WT.

Values are means±SD, n=5 per group.

Mdr2^{-/-}+Cu, curcumin-treated *Mdr2*^{-/-} mice; WT, wild type.

(NR1C3), NF-κB and extracellular signal-regulated kinase (ERK) signalling as mechanisms shown to mediate proliferation and activation of fibrogenic cells.^{30–34} Activation of MFB-like cells is associated with diminished PPARγ expression and increased ability to modulate the recruitment and activation of inflammatory cells by expression of monocyte chemoattractant protein 1 (Mcp-1).^{34–35} MFBs showed preserved basal PPARγ1 expression, which remained unchanged after curcumin incubation (data not

shown). Moreover, expression of Mcp-1, another gene altered by PPARγ ligands in fibrogenic cells,³⁴ remained unchanged in response to curcumin (figure 5C). However, curcumin profoundly inhibited 10% FCS-induced expression of activation markers Col1α2 and α-SMA in MFB cultures (figure 5C). These data led us to focus on PPARγ-independent pathways. Interestingly, cytoplasmic as well as nuclear content of pERK1/2 was dramatically reduced by curcumin (figure 5D) in portal MFBs, whereas nuclear NF-κB (p65) content remained unchanged. Under in vivo conditions, livers of curcumin-treated *Mdr2*^{-/-} mice showed a reduction of MFB activation marker α-SMA and decreased cytosolic pERK1/2 content compared with untreated littermates (figure 5E). Collectively, these data suggest that the antiproliferative effects of curcumin on MFBs could be mediated via ERK1/2 inhibition.

Curcumin attenuates reactive phenotype of bile duct epithelial cells by PPARγ activation

Cholangiopathy in *Mdr2*^{-/-} mice is characterised by increased proliferation of cholangiocytes and overexpression of pro-inflammatory cytokines and adhesion molecules (eg, VCAM-1)

Figure 5 Curcumin inhibits proliferation and activation of portal myfibroblasts. A. Portal myfibroblasts (MFBs) were isolated from *Mdr2*^{-/-} mice as described in *Materials and methods* and cytotoxic effect of curcumin was tested after 24 h incubation at concentrations of 10, 20 and 30 μM by using trypan blue dye exclusion method. Absolute number of living as well as dead cells was counted and calculated per 1 ml of cell suspension. At concentrations of 10 and 20 μM curcumin does not induce MFB cell death, whereas 30 μM is toxic. B. Influence of curcumin on MFB proliferation was assessed by immunohistochemical staining for Ki-67. Cells were first synchronised in 0% FCS containing medium and further grown on sterile cover slips using 0% FCS (to reduce proliferation), 10% FCS (to induce proliferation) and curcumin at concentrations of 10 and 20 μM in 10% FCS medium for 24 h. Number of Ki-67-positive nuclei was counted in 10 randomly chosen power fields in triplicate for each condition and the mean values of Ki-67-positive versus total cell number ratio (%) was calculated. Compared with 0% FCS condition 10% FCS stimulates MFBs proliferation, while incubation with curcumin (10 and 20 μM) reduces 10% FCS-induced proliferation of MFBs in a concentration-dependent manner. C. Curcumin effects on profibrogenic gene expression were studied in 10% FCS-activated MFBs after 24 h incubation (as described in B). Curcumin inhibits Col1α2 and α-SMA gene expression, whereas Mcp-1 expression remains unchanged. Expression levels are normalised to 18s gene expression and levels of wild type (WT) are expressed as 1. B and C: Data are presented as means±SD. *p<0.005 10% FCS vs 0% FCS, §*p*<0.005 10% FCS+Cu 10 μM vs 10% FCS, #*p*<0.005 10% FCS+Cu 20 μM vs 10% FCS. D. Cytoplasmic and nuclear proteins were isolated from MFBs after incubation with 10% FCS and 20 μM curcumin and analysed for pERK1/2 and NF-κB (p65) by Western blotting. Curcumin does not modify nuclear translocation of NF-κB, but inhibits ERK phosphorylation in portal MFBs. Representative data from two independent experiments performed in duplicate for each condition are shown. E. Proteins were isolated from livers of wild type (WT) and *Mdr2*^{-/-} mice fed either a control or a curcumin-enriched diet for 4 weeks and analysed for pERK and α-SMA by Western blotting. Curcumin significantly reduces cytoplasmic pERK1/2 in livers of *Mdr2*^{-/-} mice. Densitometry data are expressed as fold change relative to WT mice. Values are presented as means±SD. *p<0.05 *Mdr2*^{-/-} vs WT, #*p*=0.05 *Mdr2*^{-/-}+Cu vs *Mdr2*^{-/-}. Co, control; Cu, curcumin; FCS, Foetal Calf Serum; Col1α2, collagen, type I, α 2; α-SMA, α smooth muscle actin; Mcp-1, monocyte chemoattractant protein 1; CE, cytoplasmic extracts; NE, nuclear extracts.

described as reactive phenotype.^{5 17} Curcumin-treated *Mdr2*^{-/-} mice showed decreased staining for K19 as well as significantly decreased hepatic K19 content (figure 6A,B) compared with untreated *Mdr2*^{-/-} mice. In addition, bile ducts of untreated *Mdr2*^{-/-} mice were highly positive for VCAM-1 expression compared with WT mice, whereas curcumin feeding reduced VCAM-1 staining in bile ducts of *Mdr2*^{-/-} mice (figure 7A). VCAM-1 gene expression can be stimulated by pro-inflammatory cytokines such as tumour necrosis factor α (TNF- α).^{36 37} TNF- α expression was significantly increased in *Mdr2*^{-/-} mice but remained unchanged after curcumin treatment (figure 7B). In contrast, PPAR γ expression increased in both curcumin-treated WT and *Mdr2*^{-/-} mice (figure 7C), suggesting, that inhibition of production in bile duct lining cells by curcumin could be PPAR γ -mediated. In line with our *in vivo* findings, incubation of the cholangiocyte cell line HuCCT1 (expressing functionally active PPAR γ) with TNF- α induced VCAM-1 expression, which was blocked by curcumin as well as specific PPAR γ agonist troglitazone (figure 7D). Moreover, curcumin mediated inhibition of VCAM-1 expression in cholangiocytes was largely restored by pre-incubation and co-incubation with the PPAR γ synthetic antagonist BADGE (figure 7E). Together, these findings suggest, that curcumin reduced bile duct damage by inhibiting cholangiocyte activation via PPAR γ signalling.

Curcumin significantly reduces recruitment of inflammatory cells as well as hepatocellular damage and proliferation in *Mdr2*^{-/-} mice

Expression of adhesion molecules and inflammatory cytokines by bile duct cells and activated MFBs stimulates an inflammatory response in the portal tract of *Mdr2*^{-/-} mice as shown by increased CD11b levels (figure 8A). Curcumin feeding in *Mdr2*^{-/-} mice resulted in pronounced reduction of CD11b staining (figure 8A,B). In addition, compared with WT mice *Mdr2*^{-/-} mice demonstrated increased staining of lymphocyte marker CD4 in portal tracts, which was reduced by curcumin (figure 9A). However, CD8 positive cells were not detectable in *Mdr2*^{-/-} mice at this time point independent of treatment condition (figure 9B). Interestingly, expression of TNF- α , IL-1 β and TGF- β did not differ between curcumin-treated and untreated *Mdr2*^{-/-} mice (figure 7B and data not shown),

suggesting that inhibition of VCAM-1 production by cholangiocytes was sufficient to reduce infiltration by neutrophil granulocytes. Since hepatocellular proliferation is a consequence of liver damage, we next studied hepatocellular proliferation by immunohistochemical staining for the proliferation marker Ki-67. *Mdr2*^{-/-} mice showed increased amount of Ki-67-positive hepatocytes compared with WT, while curcumin reduced Ki-67-staining (figure 10A, B).

DISCUSSION

This study demonstrates that the natural compound curcumin improves bile duct injury and biliary fibrosis in a mouse model of chronic cholangiopathy. We demonstrate that curcumin targets important pathogenic steps in cholangiopathies such as MFB proliferation (via pERK1/2 inhibition) and cholangiocellular VCAM-1 expression (in a PPAR γ -dependent fashion). Taken together, curcumin reduces portal inflammation and fibrosis in the *Mdr2*^{-/-} mouse liver.

Chronic cholangiopathies include a wide spectrum of diseases ranging from autoimmune disorders (PSC, primary biliary cirrhosis, acute/chronic allograft rejection, graft vs host disease) to congenital genetic defects (Alagille syndrome, cystic fibrosis, MDR3 mutations, etc). Long-term beneficial effects of the one established medical therapy, ursodeoxycholic acid, are unclear, and liver transplantation often remains the ultimate therapeutic solution.^{38–41} Curcumin, an extract from turmeric has been used as traditional medicine for treatment of various gastrointestinal disorders.^{6–11 42} Interestingly, the early data on curcumin use date back to 1934 when pronounced choleric effects after intravenous curcumin injection were observed by using the choledochal fistula in rabbits and analysing duodenal juice in humans.⁴³ Shortly thereafter, curcumin was successfully used to treat cholestatic jaundice in patients.¹⁰ Acute choleric effects of curcumin were further confirmed in bile fistula and isolated perfused rat liver models.^{44 45} Interestingly, curcumin was also shown to reduce gallstone formation in mice after lithogenic diet feeding.⁴⁶ However, the impact of curcumin on bile composition and chronic cholangiopathies has not yet been explored.

Mdr2^{-/-} mice lacking biliary PL excretion have been characterised as a suitable mouse model for spontaneous development of sclerosing cholangitis.¹⁷ Bile duct damage and fibrosis in

Figure 6 Curcumin feeding significantly reduces bile duct proliferation in *Mdr2*^{-/-} mice. **A**, Representative immunohistochemical staining for cholangiocyte cytoskeleton marker K19 (red) shows increased ductular proliferation in *Mdr2*^{-/-} mouse compared with wild type (WT). Immunohistochemical staining for K19 does not differ between chow-fed (WT) and curcumin-fed wild type (WT+Cu) mouse, whereas 4-week curcumin-treated *Mdr2*^{-/-} mouse (*Mdr2*^{-/-}+Cu) demonstrates reduced K19 staining. **B**, Total protein was isolated from livers and analysed by Western blotting for K19 content. *Mdr2*^{-/-}+Cu mice show significantly decreased K19 protein levels compared with control diet-fed age-matched littermates. Densitometry data are expressed as fold change relative to WT mice. Values are presented as means ± SD. *p < 0.05 *Mdr2*^{-/-} vs WT, #*p* = 0.05 *Mdr2*^{-/-}+Cu vs *Mdr2*^{-/-}.

Figure 7 Curcumin decreases Vascular Cell Adhesion Molecule 1 (VCAM-1) production in bile duct epithelial cells. A. Representative immunohistochemical staining for VCAM-1 (red) in bile ducts of a chow-fed and curcumin-fed wild type (WT and WT + Cu respectively), untreated Mdr2^{-/-} and 4-week curcumin-treated Mdr2^{-/-} mouse (Mdr2^{-/-} + Cu) is shown. Bile ducts from chow-fed and curcumin-fed WT liver stain negative for VCAM-1, while bile ducts in untreated Mdr2^{-/-} liver demonstrate pronounced VCAM-1 staining. Curcumin feeding reduces VCAM-1 staining in bile ducts. bd, bile duct; pv, portal vein. B. Compared with WT mice both untreated and curcumin-treated Mdr2^{-/-} mice demonstrate increased expression of pro-inflammatory cytokine TNF-α. C. Baseline levels of PPARγ gene expression do not differ between untreated Mdr2^{-/-} mice and wild type mice (WT); both curcumin-treated WT and Mdr2^{-/-} mice (Mdr2^{-/-} + Cu) show induced PPARγ expression. B and C: Expression levels are normalised to 18s gene expression and levels of WT are expressed as 1. Values are means ± SD of five mice per group. *p < 0.05 Mdr2^{-/-} vs WT, #p < 0.05 Mdr2^{-/-} + Cu vs WT and Mdr2^{-/-}, \$p < 0.05 WT + Cu vs WT. D. TNF-α-stimulated VCAM-1 expression in cholangiocytes is blocked by curcumin. HuCCT1 cells were incubated either with TNF-α alone (to induce VCAM-1 expression) or with simultaneous TNF-α (10 ng/ml) and curcumin (10 μM) or a PPARγ specific agonist troglitazone (100 μM) for 24 h. Curcumin as well as troglitazone completely inhibit TNF-α induced VCAM-1 expression in the cholangiocyte cell line HuCCT1. E. Inhibition of VCAM-1 expression in HuCCT1 cholangiocytes by curcumin is partially restored by PPARγ synthetic antagonist BADGE. HuCCT1 cells were pre-incubated with BADGE (50 μM) for 12 h and further incubated either with curcumin alone (10 μM) or simultaneous curcumin and BADGE for 24 h. D and E: Representative experiments performed in triplicate for each condition are presented. Values are means ± SD. D: *p < 0.005 TNF-α vs Co, #p < 0.005 TNF-α + Cu vs TNF-α, \$p < 0.005 TNF-α + Trogli vs TNF-α, E: #p < 0.05 Cu vs Co, \$p < 0.05 BADGE + Cu vs Cu. Co, control; Cu, curcumin; Trogli, troglitazone.

Mdr2^{-/-} mice start early after birth and evolve over time to a full-blown phenotype at the age of 8 weeks.^{17,22} To study the potential action of curcumin on progression of liver injury in a mouse model of sclerosing cholangitis we designed 4-week and 8-week feeding protocols (figure 3A) in Mdr2^{-/-} mice starting from the time of weaning (age of 4 weeks). Formation of 'toxic bile' due to increased concentrations of non-micellar bound BAs is considered to play a central role in initiation and propagation of

bile duct injury in Mdr2^{-/-} mice.²⁹ Since curcumin feeding decreased liver damage and serum parameters of cholestasis in Mdr2^{-/-} mice, we first explored whether curcumin modulates bile flow and composition. Interestingly, the protective action of curcumin in Mdr2^{-/-} mice was not paralleled by changes of main biliary constituents, indicating that its beneficial effects may not be related to changes of bile micellisation. These data are consistent with unchanged expression of BA excretion (Bsep,

Figure 8 Recruitment of neutrophil granulocytes is reduced in portal fields of Mdr2^{-/-} mice after curcumin feeding. A. Representative immunohistochemical staining shows reduction of CD11b-positive cells in portal fields of 4-week curcumin-treated Mdr2^{-/-} mice (Mdr2^{-/-} + Cu) compared with untreated Mdr2^{-/-} mice. CD11b staining did not differ significantly between WT and WT + Cu groups. B. Portal accumulation of neutrophil granulocytes was assessed by counting the number of cells in 20 portal fields per mouse in 4–5 mice per group. Curcumin-treated Mdr2^{-/-} mice show significant reduction of CD11b-positive cells compared with age matched littermates fed a control diet. Values are means ± SD from four animals per group. *p < 0.05 Mdr2^{-/-} vs WT, #p < 0.005 Mdr2^{-/-} + Cu vs Mdr2^{-/-}.

Figure 9 Curcumin reduces recruitment of lymphocytes to the portal fields of *Mdr2*^{-/-} mice. A. Representative staining for lymphocyte marker CD4 demonstrates increased accumulation of CD4 positive cells in the portal field of *Mdr2*^{-/-} compared with wild type (WT) mouse. 4-Week curcumin feeding reduces CD4 positive lymphocyte accumulation in portal fields of *Mdr2*^{-/-} mouse. No pronounced differences are observed in curcumin-fed (WT+Cu) compared with chow-fed WT mice. B. No CD8 positive cells are detected in the portal fields of WT and *Mdr2*^{-/-} mice independent of treatment. bd, bile duct; pv, portal vein.

Mrp2, Mrp3), uptake (Ntcp) or synthesis (Cyp7a1) systems suggesting that curcumin improved serum BA levels indirectly via reduced liver damage in *Mdr2*^{-/-} mice. In line with early reports in humans^{40,43} and rats⁴⁵ curcumin feeding increased bile flow both in WT and *Mdr2*^{-/-} mice. Moreover, biliary glutathione output was increased in *Mdr2*^{-/-} as well as WT mice without changes in total hepatic glutathione content showing that glutathione synthesis is not induced by curcumin. Together with unchanged expression of canalicular Mrp2, mediating glutathione export into bile, we speculate that differences in biliary glutathione output may result from reduced biliary damage and glutathione degradation by gamma-glutamyl transpeptidase in *Mdr2*^{-/-} mice.

Bile ducts in cholangiopathies show increased proliferation and acquisition of new properties such as expression of adhesion molecule VCAM-1, a gene induced in epithelial cells in response to the pro-inflammatory cytokine TNF- α . Curcumin reduced VCAM-1 staining in cholangiocytes of *Mdr2*^{-/-} mice, while expression of stimulatory pro-inflammatory cytokines TNF- α , as well as IL-1 β and TGF- β remained unaffected. In addition, curcumin completely inhibited TNF- α -induced VCAM-1 expression in cholangiocytes in vitro. These findings support the

concept that primary inflammation and activation of cholangiocytes is an important event in the pathogenesis of cholangiopathies. Targeting cholangiocyte inflammation might represent an important strategy to cure bile duct diseases despite preserved exposure to the causative damaging factor and pro-inflammatory mediators. Previous reports in other cells have shown that curcumin may act as a PPAR γ activator.^{47–52} Since curcumin-mediated inhibition of VCAM-1 expression in HuCCT1 cells was restored by PPAR γ specific antagonist BADGE, it is attractive to speculate that inhibition of both basal and TNF- α -induced VCAM-1 expression in cholangiocytes by curcumin may be at least in part mediated by PPAR γ . Previous studies have shown reduction of bile duct proliferation and biliary fibrosis by PPAR γ agonists in bile duct-ligated rats.^{34,53} In line with these studies our data suggest that PPAR γ activation in cholangiocytes may inhibit a central pathogenetic event in cholangiopathies, namely acquisition of the cholangiocyte reactive phenotype.^{3,5}

Curcumin reduced liver fibrosis in *Mdr2*^{-/-} mice after both 4 and 8 weeks of feeding. Although relative reduction of hepatic HP levels was more pronounced after prolonged feeding (42.7% reduction after 8 weeks vs 21.9% reduction after 4 weeks), the

Figure 10 Curcumin significantly reduces hepatocellular proliferation in *Mdr2*^{-/-} mice. A. Immunohistochemical staining for proliferation marker Ki-67 (red) in a wild type (WT), 4-week curcumin-fed wild type mouse (WT+Cu), untreated *Mdr2*^{-/-} and curcumin-treated *Mdr2*^{-/-} mouse (*Mdr2*^{-/-}+Cu) is presented. Compared with WT, WT+Cu mouse shows reduced Ki-67 staining. *Mdr2*^{-/-} mouse demonstrates increased number of Ki-67-positive hepatocytes compared to WT. In contrast to untreated *Mdr2*^{-/-}, curcumin-treated *Mdr2*^{-/-} mouse shows reduced number of Ki-67-positive hepatocytes (original magnification $\times 20$). B. Ki-67-positive hepatocytes were counted in 30 high-power fields per mouse in sections of five animals per group. Curcumin feeding significantly reduces number of proliferating hepatocytes in *Mdr2*^{-/-} mice. Values are means $\pm$ SD from five animals per group. * $p < 0.05$ *Mdr2*^{-/-} vs WT, # $p < 0.05$ *Mdr2*^{-/-}+Cu vs *Mdr2*^{-/-}, § $p < 0.05$ WT+Cu vs WT.

Figure 11 Hypothetical mechanisms of curcumin action in *Mdr2*^{-/-} mice. Our data suggest that curcumin may have pleiotropic actions on several critical steps involved in the pathogenesis of liver damage and biliary fibrosis in *Mdr2*^{-/-} mice. By activation of PPAR γ in cholangiocytes, curcumin may block inflammatory granulocytes as well as myofibroblasts in the portal fields. In addition, by inhibiting the ERK1/2 signalling curcumin may decrease proliferation of portal myofibroblasts the major fibrogenic cells in *Mdr2*^{-/-} mice, thus contributing to reduction of liver fibrosis.

absolute HP levels did not differ significantly between 4 and 8 weeks of feeding, suggesting that curcumin inhibits progression of fibrosis rather than stimulating resolution of established fibrosis. A central event towards fibrosis is activation of HSCs and their transformation to MFB-like cells in response to pro-inflammatory cytokines and chemokines.^{54–55} In biliary fibrosis, the subpopulation of portal MFBs contributes greatly to fibrosis.⁵⁶ Several studies reported that activation of HSCs and their transformation to MFB-like cells with fibrogenic properties was associated with diminished level and trans-activating ability of PPAR γ , while NF- κ B activation was increased.^{31–57–60} Additionally, incubation of activated HSCs with PPAR γ agonists was shown to revert the fibrogenic phenotype of these cells by inhibiting collagen production, proliferation, migration and production of the pro-inflammatory chemokine Mcp-1.^{34–35–60–62} The importance of PPAR γ in maintaining the quiescent state of HSCs was further demonstrated by its ectopic expression in activated stellate cells resulting in inhibition of their extracellular matrix producing ability.³¹ Curcumin reduced proliferation as well as fibrotic activity of portal MFBs isolated from *Mdr2*^{-/-} mice. In contrast to previous reports, demonstrating that curcumin reduced the activated phenotype of primary HSCs by increasing PPAR γ expression and activity,^{49–50–52–63} exposure of portal MFBs to curcumin did not induce PPAR γ 1 gene expression. Moreover, curcumin did not modify Mcp-1 expression, a marker of activated MFB-like cells^{35–64} known to be inhibited by PPAR γ ligands.³⁴ Based on these findings, we suggest that curcumin had a very modest influence on PPAR γ activation in MFBs perhaps due to the lack of specific PPAR γ co-factors.

Interestingly, curcumin was shown to modulate NF- κ B and ERK signalling pathways in HSCs in vitro resulting in reduction of their activation and proliferation.^{50–49–65} Unchanged nuclear NF- κ B content after curcumin incubation is consistent with the lack of PPAR γ activation in portal MFBs. However, the reduced proliferation and activation of MFBs was associated with inhibition of ERK1/2 phosphorylation both in vitro and in vivo, suggesting that direct inhibition of ERK signalling could contribute to the reduction of biliary fibrosis by curcumin.

In agreement with the key role of inflammatory cells in the pathogenesis of PSC,^{66–67} decreased fibrosis in curcumin-treated *Mdr2*^{-/-} mice correlated with reduced CD11b and CD4 positivity. In addition, direct interaction of HSCs with CD8 positive lymphocytes was suggested to play an important role in liver

fibrosis.^{68–69} However, CD8 positive cells were virtually undetectable in both control and curcumin-treated *Mdr2*^{-/-} mice at the age of 8 weeks.

Reduced hepatocellular proliferation reflected by decreased Ki-67 staining is in line with improved liver injury in *Mdr2*^{-/-} mice. Since liver regeneration occurs in response to liver damage, it is tempting to speculate that these antiproliferative effects may result indirectly from pleiotropic effects of curcumin on different liver cell types. Moreover, antiproliferative effects of curcumin have been reported in several cancer cells,⁶³ suggesting that curcumin might also have direct antiproliferative effects in hepatocytes.

In conclusion, we demonstrate that curcumin is beneficial in a genetic mouse model of cholangiopathy and biliary fibrosis, and propose potential molecular and cellular targets of curcumin in this model (figure 11). Collectively, our findings have important implications for understanding the pathophysiology of cholangiopathies and suggest that combined targeting of cholangiocyte and MFB activation could represent a central strategy to treat or delay the progression of chronic cholangiopathies and liver fibrosis.

Acknowledgements We gratefully acknowledge Dr W Erwa (Graz) and colleagues for performing biochemical analyses of serum liver tests.

Funding This work was supported by the Austrian Science Foundation, grant numbers P18613-B05, P19118, SFB 3008 (to MT), DK56239 from NIH/NIDDK (to SJK) and by the PhD Program of Medical University of Graz.

Competing interests None.

Contributors AB: Performed the experiments, data collection, wrote the manuscript draft. MT and SJK: Conception, critical revision and correction of article, final approval of the article. PF, TC, AK: Critical revision of the article, experimental help. AF, JG, DS, KL: Data collection, technical support.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Silveira MG**, Lindor KD. Clinical features and management of primary sclerosing cholangitis. *World J Gastroenterol* 2008;**14**:3338–49.
2. **Michaels A**, Levy C. The medical management of primary sclerosing cholangitis. *Medscape J Med* 2008;**10**:61.
3. **Alvaro D**, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. *Mol Aspects Med* 2008;**29**:50–7.
4. **Alvaro D**, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. *Gastroenterology* 2007;**132**:415–31.
5. **Lazaridis KN**, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. *Gastroenterology* 2004;**127**:1565–77.

6. **Aggarwal BB**, Bhatt ID, Ichikawa H, *et al*. Curcumin — biological and medicinal properties. 2006;297–368. <http://www.indsaff.com/10%20Curcumin%20biological.pdf> (accessed 10 November 2008).
7. **Goel A**, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. *Biochem Pharmacol* 2008;**75**:787–809.
8. **Jain SK**. Ethnobotany and research on medicinal plants in India. *Ciba Found Symp* 1994;**185**:153–64.
9. **Maheshwari RK**, Singh AK, Gaddipati J, *et al*. Multiple biological activities of curcumin: a short review. *Life Sci* 2006;**78**:2081–87.
10. **Oppenheimer A**. Turmeric (curcumin) in biliary diseases. *Lancet* 1937;619–21.
11. **Rasyid A**, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. *Aliment Pharmacol Ther* 1999;**13**:245–9.
12. **Fu Y**, Zheng S, Lin J, *et al*. Curcumin protects the rat liver from CCl₄-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. *Mol Pharmacol* 2008;**73**:399–409.
13. **Reyes-Gordillo K**, Segovia J, Shibayama M, *et al*. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl₄ in rats: role of TGF- β modulation and oxidative stress. *Fundam Clin Pharmacol* 2008;**22**:417–27.
14. **Reyes-Gordillo K**, Segovia J, Shibayama M, *et al*. Curcumin protects against acute liver damage in the rat by inhibiting NF- κ B, proinflammatory cytokines production and oxidative stress. *Biochim Biophys Acta* 2007;**1770**:989–96.
15. **Zhao ZS**, O'Brien PJ. The prevention of CCl₄-induced liver necrosis in mice by naturally occurring methylenedioxybenzenes. *Toxicol Appl Pharmacol* 1996;**140**:411–21.
16. **Li D**, Zimmerman TL, Thevananthar S, *et al*. Interleukin-1 β -mediated suppression of RXR: RAR transactivation of the Ntcp promoter is JNK-dependent. *J Biol Chem* 2002;**277**:31416–22.
17. **Fickert P**, Fuchsichler A, Wagner M, *et al*. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology* 2004;**127**:261–74.
18. **Fickert P**, Wagner M, Marschall HU, *et al*. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology* 2006;**130**:465–81.
19. **Trauner M**, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. *Physiol Rev* 2003;**83**:633–71.
20. **Trauner M**, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. *Semin Liver Dis* 2007;**27**:77–98.
21. **Trauner M**, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. *N Engl J Med* 1998;**339**:1217–27.
22. **Popov Y**, Patsenker E, Fickert P, *et al*. Mdr2 (Abcb4)^{−/−} mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. *J Hepatol* 2005;**43**:1045–54.
23. **Jamali IS**, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. *Anal Biochem* 1981;**112**:70–5.
24. **Trauner M**, Arrese M, Soroka CJ, *et al*. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. *Gastroenterology* 1997;**113**:255–64.
25. **Fickert P**, Zollner G, Fuchsichler A, *et al*. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. *Gastroenterology* 2001;**121**:170–83.
26. **Zollner G**, Fickert P, Silbert D, *et al*. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *J Hepatol* 2003;**38**:717–27.
27. **Wagner M**, Fickert P, Zollner G, *et al*. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. *Gastroenterology* 2003;**125**:825–38.
28. **Uchio K**, Tuchweber B, Manabe N, *et al*. Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts. *Lab Invest* 2002;**82**:619–28.
29. **Trauner M**, Fickert P, Halilbasic E, *et al*. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. *Wien Med Wochenschr* 2008;**158**:542–48.
30. **Chen A**, Zheng S. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF- κ B and ERK signalling. *Br J Pharmacol* 2008;**153**:557–67.
31. **Hazra S**, Xiong S, Wang J, *et al*. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. *J Biol Chem* 2004;**279**:11392–401.
32. **Hellerbrand C**, Jobin C, Imuro Y, *et al*. Inhibition of NF- κ B in activated rat hepatic stellate cells by proteasome inhibitors and an I κ B super-repressor. *Hepatology* 1998;**27**:1285–95.
33. **Hellerbrand C**, Jobin C, Licato LL, *et al*. Cytokines induce NF- κ B in activated but not in quiescent rat hepatic stellate cells. *Am J Physiol* 1998;**275**:G269–78.
34. **Marra F**, Efsen E, Romanelli RG, *et al*. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. *Gastroenterology* 2000;**119**:466–78.
35. **Marra F**, DeFranco R, Grappone C, *et al*. Increased expression of monocyte chemoattractant protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. *Am J Pathol* 1998;**152**:423–30.
36. **Osborn L**, Hession C, Tizard R, *et al*. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. *Cell* 1989;**59**:1203–11.
37. **Kelly M**, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. *J Allergy Clin Immunol* 2007;**120**:3–10.
38. **Cullen SN**, Rust C, Fleming K, *et al*. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. *J Hepatol* 2008;**48**:792–800.
39. **De Maria N**, Colantoni A, Rosenbloom E, *et al*. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. *Hepatogastroenterology* 1996;**43**:1472–9.
40. **Gong Y**, Huang ZB, Christensen E, *et al*. Ursodeoxycholic acid for primary biliary cirrhosis. *Cochrane Database Syst Rev* 2008(3):CD000551. doi:10.1002/14651858.CD000551.pub2
41. **Shi J**, Wu C, Lin Y, *et al*. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2006;**101**:1529–38.
42. **Sharma RA**, McLelland HR, Hill KA, *et al*. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. *Clin Cancer Res* 2001;**7**:1894–1900.
43. **Henning NaK O**. Untersuchungen über Resorption und Ausscheidung des Curcumins. *Münchener Medizinische Wochenschrift* 1934;**42**:1611.
44. **Chen C**, Johnston TD, Wu G, *et al*. Curcumin has potent liver preservation properties in an isolated perfusion model. *Transplantation* 2006;**82**:931–7.
45. **Deters M**, Siegers C, Muhl P, *et al*. Choleretic effects of curcuminoids on an acute cyclosporin-induced cholestasis in the rat. *Planta Med* 1999;**65**:610–3.
46. **Hussain MS**, Chandrasekhara N. Effect on curcumin on cholesterol gall-stone induction in mice. *Indian J Med Res* 1992;**96**:288–91.
47. **Jacob A**, Wu R, Zhou M, *et al*. Mechanism of the anti-inflammatory effect of curcumin: ppar-gamma activation. *PPAR Res* 2007;**2007**:89369.
48. **Lin J**, Chen A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. *Lab Invest* 2008;**88**:529–40.
49. **Xu J**, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. *Am J Physiol Gastrointest Liver Physiol* 2003;**285**:G20–30.
50. **Zheng S**, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. *Biochem J* 2004;**384**:149–57.
51. **Zheng S**, Chen A. Disruption of transforming growth factor- β signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2007;**292**:G113–123.
52. **Zhou Y**, Zheng S, Lin J, *et al*. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. *Lab Invest* 2007;**87**:488–98.
53. **Marra F**, DeFranco R, Robino G, *et al*. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. *World J Gastroenterol* 2005;**11**:4931–8.
54. **Battaller R**, Brenner DA. Liver fibrosis. *J Clin Invest* 2005;**115**:209–18.
55. **Friedman SL**. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* 2000;**275**:2247–50.
56. **Cassiman D**, Libbrecht L, Desmet V, *et al*. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. *J Hepatol* 2002;**36**:200–9.
57. **Eng FJ**, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. *Am J Physiol Gastrointest Liver Physiol* 2000;**279**:G7–G11.
58. **Hazra S**, Miyahara T, Rippe RA, *et al*. PPAR gamma and hepatic stellate cells. *Comp Hepatol* 2004;**3**(Suppl 1):S7.
59. **Mann DA**, Smart DE. Transcriptional regulation of hepatic stellate cell activation. *Gut* 2002;**50**:891–6.
60. **Miyahara T**, Schrum L, Rippe R, *et al*. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. *J Biol Chem* 2000;**275**:35715–22.
61. **Galli A**, Crabb D, Price D, *et al*. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. *Hepatology* 2000;**31**:101–8.
62. **Galli A**, Crabb DW, Ceni E, *et al*. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. *Gastroenterology* 2002;**122**:1924–40.
63. **Kunnumakkara AB**, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett* 2008;**269**:199–225.
64. **Maher JJ**, Lozier JS, Scott MK. Rat hepatic stellate cells produce cytokine-induced neutrophil chemoattractant in culture and in vivo. *Am J Physiol* 1998;**275**:G847–53.
65. **Cheng Y**, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells. *Chin Med J (Engl)* 2007;**120**:794–801.
66. **O'Mahony CA**, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. *Semin Liver Dis* 2006;**26**:3–21.
67. **Chapman R**, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. *World J Gastroenterol* 2008;**14**:3350–9.
68. **Sfadi R**, Ohta M, Alvarez CE, *et al*. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology* 2004;**127**:870–82.
69. **Muhanna N**, Horani A, Doron S, *et al*. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. *Clin Exp Immunol* 2007;**148**:338–47.